Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 12Rituximab 10Peripheral Blood Stem Cell Transplantation 8fludarabine phosphate 7Etoposide 5fludarabine 4Radiotherapy 4Filgrastim 4Cytarabine 4venetoclax 3ofatumumab 3Whole-Body Irradiation 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Doxorubicin 3Cyclosporine 3Carmustine 3Bendamustine Hydrochloride 3sargramostim 2romidepsin 2idelalisib 2ibrutinib 2ibritumomab tiuxetan 2Saline Solution 2Prednisone 2Pentetic Acid 2Ondansetron 2O(6)-benzylguanine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, Non-Hodgkin × AP 1903 reagent × Clear all
NCT02487459 2020-10-05

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡